Your AI-Trained Oncology Knowledge Connection!

Tokujiro Yano, MD

Articles

UFT Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer

Yukito Ichinose, MD;Tokujiro Yano, MD;Hiroshi Asoh, MD;Hideki Yokoyama, MD;Riichiroh Maruyama, MD;Chie Ushijima, MD;Tadashi Uehara, MD;Takanori Kanematsu, MD;Tomofumi Yohena, MD;Susumu Wada, MD

July 1st 1999

A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in

UFT Plus Cisplatin in Advanced Non-Small-Cell Lung Cancer: Interim Analysis of 67 Patients

Tokujiro Yano, MD;Shoji Kudoh, MD;Kozo Yoshimori, MD;Tetsuyuki Morikawa, MD;Mutsuo Kuba, MD;Hisanobu Niitani, MD

September 2nd 1997

A single-institution phase II study indicated that combination chemotherapy using UFT (tegafur and uracil) plus cisplatin (Platinol) in patients with non-small-cell lung cancer was active with less host toxicity than other cisplatin-